Eurofins Scientific SE
PAR:ERF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (10.8), the stock would be worth €69.74 (12% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.6 | €62 |
0%
|
| 3-Year Average | 10.8 | €69.74 |
+12%
|
| 5-Year Average | 12.5 | €80.4 |
+30%
|
| Industry Average | 11.9 | €76.5 |
+23%
|
| Country Average | 9.6 | €61.85 |
0%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| LU |
|
Eurofins Scientific SE
PAR:ERF
|
11.1B EUR | 9.6 | 26.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 774.1 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.4B USD | 25.2 | 25.8 | |
| US |
|
Danaher Corp
NYSE:DHR
|
130.1B USD | 21.7 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.9B CHF | 31.9 | -122.3 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
296.1B CNY | 15.3 | 15.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.1B USD | 24.4 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.8B USD | 47.5 | 47.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
29.7B USD | 14.7 | 20 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.7B USD | 28.7 | 29.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 6 |
| Median | 9.6 |
| 70th Percentile | 15.1 |
| Max | 462.4 |
Other Multiples
Eurofins Scientific SE
Glance View
In the intricate realm of scientific services, Eurofins Scientific SE emerges as a quintessential powerhouse, orchestrating a symphony of analysis and testing across various industries. Founded in 1987, Eurofins began its journey with a focus on groundbreaking scientific methods for food and agriculture sectors. However, it rapidly diversified its expertise, leveraging its analytical prowess to expand into pharmaceuticals, environmental testing, and clinical diagnostics. The company operates through a network of laboratories scattered across the globe, each one serving as a beacon of quality and precision, embodying Eurofins' commitment to safeguarding consumer health, ensuring product safety, and supporting regulatory compliance. This robust infrastructure allows Eurofins to produce a constant stream of detailed and reliable test results, fueling its reputation and securing its place in the global market. Eurofins generates revenue primarily through its comprehensive suite of testing services, which cut across multiple sectors. Clients range from large corporations and government bodies to individual consumers who require specific tests. The company capitalizes on its broad spectrum of specialized tests, from determining the complex composition of food products to detecting elusive contaminants in pharmaceuticals and performing critical genetic screenings. This creates a diversified revenue stream that minimizes dependency on any single industry or service line. Eurofins' ability to continuously innovate and adapt its offerings ensures an ongoing inflow of clients seeking unparalleled testing accuracy and expertise. The combination of this vast service portfolio and relentless pursuit of scientific advancement underpins Eurofins' impressive financial performance and solidifies its pivotal role in the scientific services industry.